Stay away from concomitant usage of tucatinib with CYP3A substrates, where by minimum concentration improvements may well cause really serious or lifetime-threatening toxicities. If unavoidable, lessen CYP3A substrate dose In accordance with product labeling.Reserve concomitant prescribing of such medicine for use in clients for whom alternate reme